Citius Oncology's Q3 Loss, Going Concern Warning, and Nasdaq Delisting Risk
CTOR sits 80% above its 52-week low of $0.491 on elevated volume (2.8× avg).
Summary
Citius Oncology's Q3 10-Q shows deepening losses, a going concern warning, Nasdaq delisting risk, and a $19.7M CMO termination fee.
Key Events · Earnings and Guidance · CTOR
-
Q3 Net Loss Widens
Net loss of $8.9M for Q3 FY2026, up from $5.4M a year ago; nine-month loss of $41.1M vs $19.8M prior year.
-
Going Concern Warning
Management states substantial doubt about ability to continue as a going concern; cash runway only through November 2026.
-
Nasdaq Delisting Notice
Received April 22, 2026 for bid price below $1.00; compliance deadline October 19, 2026.
-
CMO Termination Fee
Contract manufacturer terminated agreement due to payment breach; $19.7M cancellation fee recorded in March 2026.
Analysis · CTOR · Life Sciences
The Q3 FY2026 10-Q from Citius Oncology shows a net loss of $8.9 million for the quarter and $41.1 million for the nine months, with only $16.6 million in cash and a negative working capital of $16.1 million. Management states substantial doubt about the company's ability to continue as a going concern, with cash runway only through November 2026. The company also received a Nasdaq delisting notice on April 22, 2026, and must regain compliance by October 19, 2026. Additionally, a contract manufacturing organization terminated its agreement due to payment breaches, resulting in a $19.7 million cancellation fee. These factors collectively indicate severe financial distress and significant risk to shareholders.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 44.4% of the 293 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.30%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTOR was trading at $0.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $84.6M. The 52-week trading range was $0.49 to $2.25. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.